Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria.

Brodsky RA, Peffault de Latour R, Rottinghaus ST, Röth A, Risitano AM, Weitz IC, Hillmen P, Maciejewski JP, Szer J, Lee JW, Kulasekararaj AG, Volles L, Damokosh AI, Ortiz S, Shafner L, Liu P, Hill A, Schrezenmeier H.

Haematologica. 2020 Jan 16. pii: haematol.2019.236877. doi: 10.3324/haematol.2019.236877. [Epub ahead of print]

PMID:
31949012
2.

Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party.

Prata PH, Eikema DJ, Afansyev B, Bosman P, Smiers F, Diez-Martin JL, Arrais-Rodrigues C, Koc Y, Poiré X, Sirvent A, Kröger N, Porta F, Holter W, Bloor A, Jubert C, Ganser A, Tanase A, Ménard AL, Pioltelli P, Pérez-Simón JA, Ho A, Aljurf M, Russell N, Labussiere-Wallet H, Kerre T, Rocha V, Socié G, Risitano A, Dufour C, Peffault de Latour R; SAA WP of the EBMT.

Bone Marrow Transplant. 2019 Dec 16. doi: 10.1038/s41409-019-0773-0. [Epub ahead of print]

PMID:
31844137
3.

Author Correction: 'Stealth' corporate innovation: an emerging threat for therapeutic drug development.

Mastellos DC, Blom AM, Connolly ES, Daha MR, Geisbrecht BV, Ghebrehiwet B, Gros P, Hajishengallis G, Holers VM, Huber-Lang M, Kinoshita T, Mollnes TE, Montgomery RA, Morgan BP, Nilsson B, Pio R, Ricklin D, Risitano AM, Taylor RP, Mantovani A, Ioannidis JPA, Lambris JD.

Nat Immunol. 2019 Nov;20(11):1556. doi: 10.1038/s41590-019-0531-x.

PMID:
31605100
4.

Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globuline, cyclosporine, with or without G-CSF: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation.

Tichelli A, Peffault de Latour R, Passweg J, Knol-Bout C, Socié G, Marsh J, Schrezenmeier H, Höchsmann B, Bacigalupo A, Samarasinghe S, Rovó A, Kulasekararaj A, Röth A, Eikema DJ, Bosman P, Bader P, Risitano A, Dufour C; Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation.

Haematologica. 2019 Oct 3. pii: haematol.2019.222562. doi: 10.3324/haematol.2019.222562. [Epub ahead of print]

5.

T-PLL: harmonizing criteria for research.

Risitano AM.

Blood. 2019 Oct 3;134(14):1113-1114. doi: 10.1182/blood.2019002303. No abstract available.

PMID:
31582368
6.

'Stealth' corporate innovation: an emerging threat for therapeutic drug development.

Mastellos DC, Blom AM, Connolly ES, Daha MR, Geisbrecht BV, Ghebrehiwet B, Gros P, Hajishengallis G, Holers VM, Huber-Lang M, Kinoshita T, Mollnes TE, Montgomery RA, Morgan BP, Nilsson B, Pio R, Ricklin D, Risitano AM, Taylor RP, Mantovani A, Ioannidis JPA, Lambris JD.

Nat Immunol. 2019 Nov;20(11):1409-1413. doi: 10.1038/s41590-019-0503-1. No abstract available. Erratum in: Nat Immunol. 2019 Oct 11;:.

PMID:
31562490
7.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO).

Candoni A, Rambaldi A, Fanin R, Velardi A, Arcese W, Ciceri F, Lazzarotto D, Lussana F, Olivieri J, Grillo G, Parma M, Bruno B, Sora F, Bernasconi P, Saccardi R, Foà R, Sessa M, Bresciani P, Giglio F, Picardi A, Busca A, Sica S, Perruccio K, Zucchetti E, Diral E, Iori AP, Colombo AA, Tringali S, Santarone S, Irrera G, Mancini S, Zallio F, Malagola M, Albano F, Carella AM, Olivieri A, Tecchio C, Dominietto A, Vacca A, Sorasio R, Orciuolo E, Risitano AM, Leotta S, Cortelezzi A, Mammoliti S, Oldani E, Bonifazi F; GITMO.

Biol Blood Marrow Transplant. 2019 Dec;25(12):2388-2397. doi: 10.1016/j.bbmt.2019.07.037. Epub 2019 Aug 7.

PMID:
31400502
8.

Allogeneic stem cell transplantation for acquired pure red cell aplasia.

Halkes C, de Wreede LC, Knol C, Simand C, Aljurf M, Tbakhi A, Vazquez L, Bloor A, Wagner-Drouet E, Vural F, Bodova I, Isaksson C, Diaz MÁ, Gruhn B, Snowden J, Arat M, Bazarbachi A, Spilleboudt C, Kulagin A, Marsh JC, Passweg J, Risitano AM, Peffault de Latour R, Dufour C; European Society for Blood and Marrow Transplantation Severe Aplastic Anemia Working Party.

Am J Hematol. 2019 Nov;94(11):E294-E296. doi: 10.1002/ajh.25609. Epub 2019 Sep 9. No abstract available.

PMID:
31396977
9.

Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.

Risitano AM, Marotta S, Ricci P, Marano L, Frieri C, Cacace F, Sica M, Kulasekararaj A, Calado RT, Scheinberg P, Notaro R, Peffault de Latour R.

Front Immunol. 2019 Jun 14;10:1157. doi: 10.3389/fimmu.2019.01157. eCollection 2019. Review.

10.

Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention.

Paciaroni M, Agnelli G, Caso V, Silvestrelli G, Seiffge DJ, Engelter S, De Marchis GM, Polymeris A, Zedde ML, Yaghi S, Michel P, Eskandari A, Antonenko K, Sohn SI, Cappellari M, Tassinari T, Tassi R, Masotti L, Katsanos AH, Giannopoulos S, Acciarresi M, Alberti A, Venti M, Mosconi MG, Vedovati MC, Pierini P, Giustozzi M, Lotti EM, Ntaios G, Kargiotis O, Monaco S, Lochner P, Bandini F, Liantinioti C, Palaiodimou L, Abdul-Rahim AH, Lees K, Mancuso M, Pantoni L, Rosa S, Bertora P, Galliazzo S, Ageno W, Toso E, Angelini F, Chiti A, Orlandi G, Denti L, Flomin Y, Marcheselli S, Mumoli N, Rimoldi A, Verrengia E, Schirinzi E, Del Sette M, Papamichalis P, Komnos A, Popovic N, Zarkov M, Rocco A, Diomedi M, Giorli E, Ciccone A, Mac Grory BC, Furie KL, Bonetti B, Saia V, Guideri F, Acampa M, Martini G, Grifoni E, Padroni M, Karagkiozi E, Perlepe K, Makaritsis K, Mannino M, Maccarrone M, Ulivi L, Giannini N, Ferrari E, Pezzini A, Doronin B, Volodina V, Baldi A, D'Amore C, Deleu D, Corea F, Putaala J, Santalucia P, Nardi K, Risitano A, Toni D, Tsivgoulis G.

Stroke. 2019 Aug;50(8):2168-2174. doi: 10.1161/STROKEAHA.119.025350. Epub 2019 Jun 25.

PMID:
31234756
11.

The Case for Upfront HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation as a Curative Option for Adult Acquired Severe Aplastic Anemia.

Marsh JCW, Risitano AM, Mufti GJ.

Biol Blood Marrow Transplant. 2019 Sep;25(9):e277-e284. doi: 10.1016/j.bbmt.2019.05.012. Epub 2019 May 24. Review.

PMID:
31129354
12.

Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.

Schubart A, Anderson K, Mainolfi N, Sellner H, Ehara T, Adams CM, Mac Sweeney A, Liao SM, Crowley M, Littlewood-Evans A, Sarret S, Wieczorek G, Perrot L, Dubost V, Flandre T, Zhang Y, Smith RJH, Risitano AM, Karki RG, Zhang C, Valeur E, Sirockin F, Gerhartz B, Erbel P, Hughes N, Smith TM, Cumin F, Argikar UA, Haraldsson B, Mogi M, Sedrani R, Wiesmann C, Jaffee B, Maibaum J, Flohr S, Harrison R, Eder J.

Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7926-7931. doi: 10.1073/pnas.1820892116. Epub 2019 Mar 29.

13.

Use of eltrombopag in aplastic anemia in Europe.

Ecsedi M, Lengline É, Knol-Bout C, Bosman P, Eikema DJ, Afanasyev B, Maschan A, Dreger P, Halkes CJM, Drexler B, Cortelezzi A, Drénou B, Patriarca A, Bruno B, Onofrillo D, Lanino E, Pulanic D, Serventi-Seiwerth R, Garnier A, Ljungman P, Bonifazi F, Giammarco S, Tournilhac O, Pioltelli P, Rovó A, Risitano AM, de Latour RP, Dufour C, Passweg J; EBMT SAA Working Party.

Ann Hematol. 2019 Jun;98(6):1341-1350. doi: 10.1007/s00277-019-03652-8. Epub 2019 Mar 26.

PMID:
30915499
14.

Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.

Bonifazi F, Solano C, Wolschke C, Sessa M, Patriarca F, Zallio F, Nagler A, Selleri C, Risitano AM, Messina G, Bethge W, Herrera P, Sureda A, Carella AM, Cimminiello M, Guidi S, Finke J, Sorasio R, Ferra C, Sierra J, Russo D, Benedetti E, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Kröger N.

Lancet Haematol. 2019 Feb;6(2):e89-e99. doi: 10.1016/S2352-3026(18)30214-X. Erratum in: Lancet Haematol. 2019 Mar;6(3):e121.

PMID:
30709437
15.

Eltrombopag for post-transplant cytopenias due to poor graft function.

Marotta S, Marano L, Ricci P, Cacace F, Frieri C, Simeone L, Trastulli F, Vitiello S, Cardano F, Pane F, Risitano AM.

Bone Marrow Transplant. 2019 Aug;54(8):1346-1353. doi: 10.1038/s41409-019-0442-3. Epub 2019 Jan 24.

PMID:
30679824
16.

Stem cell transplantation for congenital dyserythropoietic anemia: an analysis from the European Society for Blood and Marrow Transplantation.

Miano M, Eikema DJ, Aljurf M, Van't Veer PJ, Öztürk G, Wölfl M, Smiers F, Schulz A, Socié G, Vettenranta K, de Heredia CD, Zecca M, Maertens J, Rovira M, Sierra J, Uckan-Cetinkaya D, Skorobogatova E, Antmen AB, Dalle JH, Markiewicz M, Hamladji RM, Kitra-Roussou V, La Nasa G, Kriván G, Al-Seiraihy A, Giardino S, Risitano AM, de Latour RP, Dufour C.

Haematologica. 2019 Aug;104(8):e335-e339. doi: 10.3324/haematol.2018.206623. Epub 2019 Jan 24. No abstract available.

17.

Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule.

Lombardi E, Matte A, Risitano AM, Ricklin D, Lambris JD, De Zanet D, Jokiranta ST, Martinelli N, Scambi C, Salvagno G, Bisoffi Z, Colato C, Siciliano A, Bortolami O, Mazzuccato M, Zorzi F, De Marco L, De Franceschi L.

Haematologica. 2019 May;104(5):919-928. doi: 10.3324/haematol.2018.198622. Epub 2019 Jan 10.

18.

Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.

Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, Gaya A, Lee JW, Gutierrez EO, Piatek CI, Szer J, Risitano A, Nakao S, Bachman E, Shafner L, Damokosh AI, Ortiz S, Röth A, Peffault de Latour R.

Blood. 2019 Feb 7;133(6):540-549. doi: 10.1182/blood-2018-09-876805. Epub 2018 Dec 3.

19.

[Network references for rare diseases: state of the art for the paroxysmal nocturnal hemoglobinuria].

Alfano R, Palladino R, Risitano A, De Pascale T, Raia M, Castrianni D, Scamardo MS, Cerbone V, Schiavone D, D'Onofrio G, Buonocore G, Triassi M, Del Vecchio L, Rubba F.

Epidemiol Prev. 2018 Sep-Dec;42(5-6):333-343. doi: 10.19191/EP18.5-6.P333.102. Review. Italian.

PMID:
30370735
20.

Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party.

Samarasinghe S, Clesham K, Iacobelli S, Sbianchi G, Knol C, Hamladji RM, Socié G, Aljurf M, Koh M, Sengeloev H, Dalle JH, Robinson S, Van Lint MT, Halkes CJM, Beelen D, Mufti GJ, Snowden J, Blaise D, de Latour RP, Marsh J, Dufour C, Risitano AM; Severe Aplastic Anaemia Working Party of the EBMT.

Am J Hematol. 2019 Jan;94(1):80-86. doi: 10.1002/ajh.25314. Epub 2018 Nov 25.

21.

Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Mastellos DC, Reis ES, Yancopoulou D, Risitano AM, Lambris JD.

Semin Hematol. 2018 Jul;55(3):167-175. doi: 10.1053/j.seminhematol.2018.02.002. Epub 2018 Feb 14. Review.

22.

Therapeutic complement modulation for hematological diseases: Where we stand and where we are going.

Risitano AM.

Semin Hematol. 2018 Jul;55(3):113-117. doi: 10.1053/j.seminhematol.2018.05.012. Epub 2018 May 29. No abstract available.

PMID:
30032746
23.

Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita.

Fioredda F, Iacobelli S, Korthof ET, Knol C, van Biezen A, Bresters D, Veys P, Yoshimi A, Fagioli F, Mats B, Zecca M, Faraci M, Miano M, Arcuri L, Maschan M, O'Brien T, Diaz MA, Sevilla J, Smith O, Peffault de Latour R, de la Fuente J, Or R, Van Lint MT, Tolar J, Aljurf M, Fisher A, Skorobogatova EV, Diaz de Heredia C, Risitano A, Dalle JH, Sedláček P, Ghavamzadeh A, Dufour C.

Br J Haematol. 2018 Oct;183(1):110-118. doi: 10.1111/bjh.15495. Epub 2018 Jul 9.

PMID:
29984823
24.

Advances in understanding the pathogenesis of acquired aplastic anaemia.

Luzzatto L, Risitano AM.

Br J Haematol. 2018 Sep;182(6):758-776. doi: 10.1111/bjh.15443. Epub 2018 Jul 5. Review.

PMID:
29974931
25.

(Auto-)immune signature in aplastic anemia.

Risitano AM.

Haematologica. 2018 May;103(5):747-749. doi: 10.3324/haematol.2018.190884. No abstract available.

26.

Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria.

Risitano AM, Marotta S.

Am J Hematol. 2018 Aug;93(4):564-577. doi: 10.1002/ajh.25016. Epub 2018 Jan 25. Review.

27.

Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation.

Rovó A, Kulasekararaj A, Medinger M, Chevallier P, Ribera JM, Peffault de Latour R, Knol C, Iacobelli S, Kanfer E, Bruno B, Maury S, Quarello P, Koh MBC, Schouten H, Blau IW, Tichelli A, Hill A, Risitano A, Passweg J, Marsh J, Dreger P, Dufour C; Severe Aplastic Anaemia Working Party of the EBMT.

Br J Haematol. 2019 Jan;184(2):294-298. doi: 10.1111/bjh.15074. Epub 2017 Dec 19. No abstract available.

PMID:
29265360
28.

Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis.

Pagliuca S, Risitano AM, De Fontbrune FS, Robin M, Iori AP, Marotta S, Michonneau D, Villate A, Desmier D, Socié G, De Latour RP.

Bone Marrow Transplant. 2018 Jan;53(1):105-107. doi: 10.1038/bmt.2017.220. Epub 2017 Nov 13. No abstract available.

PMID:
29131151
29.

Transplant results in adults with Fanconi anaemia.

Bierings M, Bonfim C, Peffault De Latour R, Aljurf M, Mehta PA, Knol C, Boulad F, Tbakhi A, Esquirol A, McQuaker G, Sucak GA, Othman TB, Halkes CJM, Carpenter B, Niederwieser D, Zecca M, Kröger N, Michallet M, Risitano AM, Ehninger G, Porcher R, Dufour C; EBMT SAA WP.

Br J Haematol. 2018 Jan;180(1):100-109. doi: 10.1111/bjh.15006. Epub 2017 Nov 2.

PMID:
29094350
30.

Acute immune toxicity during anti-thymocyte globulin: That's CARPA!

Marotta S, Ricci P, Marano L, Beneduce G, Vitagliano O, De Gregorio F, Grimaldi F, Pane F, Risitano AM.

Am J Hematol. 2018 Jan;93(1):E22-E24. doi: 10.1002/ajh.24945. Epub 2017 Nov 3. No abstract available.

31.

Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose Cyclophosphamide.

Raiola AM, Risitano A, Sacchi N, Giannoni L, Signori A, Aquino S, Bregante S, Di Grazia C, Dominietto A, Geroldi S, Ghiso A, Gualandi F, Lamparelli T, Tedone E, Van Lint MT, Varaldo R, Ibatici A, Marani C, Marotta S, Guolo F, Avenoso D, Garbarino L, Pane F, Bacigalupo A, Angelucci E.

Biol Blood Marrow Transplant. 2018 Jan;24(1):119-126. doi: 10.1016/j.bbmt.2017.10.002. Epub 2017 Oct 9.

32.

Steroid treatment of acute graft-versus-host disease grade I: a randomized trial.

Bacigalupo A, Milone G, Cupri A, Severino A, Fagioli F, Berger M, Santarone S, Chiusolo P, Sica S, Mammoliti S, Sorasio R, Massi D, Van Lint MT, Raiola AM, Gualandi F, Selleri C, Sormani MP, Signori A, Risitano A, Bonifazi F; Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

Haematologica. 2017 Dec;102(12):2125-2133. doi: 10.3324/haematol.2017.171157. Epub 2017 Sep 29.

33.

Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions.

Thota S, Patel BJ, Sadaps M, Balasubramanian S, Sanikommu S, Hirsch C, Marotta S, Sekeres MA, Risitano AM, Maciejewski JP.

Br J Haematol. 2018 Oct;183(1):133-136. doi: 10.1111/bjh.14907. Epub 2017 Sep 14. No abstract available.

PMID:
28905372
34.

Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.

Sica M, Rondelli T, Ricci P, De Angioletti M, Risitano AM, Notaro R.

J Hematol Oncol. 2017 Jun 19;10(1):126. doi: 10.1186/s13045-017-0496-x.

35.

Immune insights into AA.

Risitano AM.

Blood. 2017 May 25;129(21):2824-2826. doi: 10.1182/blood-2017-03-771493. No abstract available.

PMID:
28546224
36.

New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?

Patriarca F, Giaccone L, Onida F, Castagna L, Sarina B, Montefusco V, Mussetti A, Mordini N, Maino E, Greco R, Peccatori J, Festuccia M, Zaja F, Volpetti S, Risitano A, Bassan R, Corradini P, Ciceri F, Fanin R, Baccarani M, Rambaldi A, Bonifazi F, Bruno B.

Expert Opin Biol Ther. 2017 Jul;17(7):821-836. doi: 10.1080/14712598.2017.1324567. Epub 2017 May 22. Review.

PMID:
28506131
37.

Narrative Based Medicine as a tool for needs assessment of patients undergoing hematopoietic stem cell transplantation.

Gargiulo G, Sansone V, Rea T, Artioli G, Botti S, Continisio GI, Ferri P, Masi D, Risitano AM, Simeone S, La Sala R.

Acta Biomed. 2017 Mar 14;88(1S):18-24. doi: 10.23750/abm.v88i1 -S.6280.

PMID:
28327491
38.

Small-molecule factor D inhibitors targeting the alternative complement pathway.

Maibaum J, Liao SM, Vulpetti A, Ostermann N, Randl S, Rüdisser S, Lorthiois E, Erbel P, Kinzel B, Kolb FA, Barbieri S, Wagner J, Durand C, Fettis K, Dussauge S, Hughes N, Delgado O, Hommel U, Gould T, Mac Sweeney A, Gerhartz B, Cumin F, Flohr S, Schubart A, Jaffee B, Harrison R, Risitano AM, Eder J, Anderson K.

Nat Chem Biol. 2016 Dec;12(12):1105-1110. doi: 10.1038/nchembio.2208. Epub 2016 Oct 24.

PMID:
27775713
39.

Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia.

Lindorfer MA, Cook EM, Reis ES, Ricklin D, Risitano AM, Lambris JD, Taylor RP.

Clin Immunol. 2016 Oct;171:32-35. doi: 10.1016/j.clim.2016.08.017. Epub 2016 Aug 18.

40.

Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.

Risitano AM, Marotta S.

Semin Immunol. 2016 Jun;28(3):223-40. doi: 10.1016/j.smim.2016.05.001. Epub 2016 Jun 23. Review.

PMID:
27346521
41.

Paroxysmal nocturnal hemoglobinuria in the era of complement inhibition.

Risitano AM.

Am J Hematol. 2016 Jun;91(4):359-60. doi: 10.1002/ajh.24323. No abstract available.

42.

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.

Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, Pérez de Oteiza J, Duarte R, Carella AM, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Bonifazi F.

N Engl J Med. 2016 Jan 7;374(1):43-53. doi: 10.1056/NEJMoa1506002.

43.

Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.

Hillmen P, Muus P, Szer J, Hill A, Höchsmann B, Kulasekararaj A, Risitano AM, Van Den Neste E, Liljeholm M, Ebrahim KS, Bedrosian CL, Gao X, Ames D, Socié G.

Am J Hematol. 2016 Mar;91(3):E16-7. doi: 10.1002/ajh.24280. No abstract available.

44.

Twenty years of the Italian Fanconi Anemia Registry: where we stand and what remains to be learned.

Risitano AM, Marotta S, Calzone R, Grimaldi F, Zatterale A; RIAF Contributors.

Haematologica. 2016 Mar;101(3):319-27. doi: 10.3324/haematol.2015.133520. Epub 2015 Dec 3.

45.

Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial.

Rambaldi A, Grassi A, Masciulli A, Boschini C, Micò MC, Busca A, Bruno B, Cavattoni I, Santarone S, Raimondi R, Montanari M, Milone G, Chiusolo P, Pastore D, Guidi S, Patriarca F, Risitano AM, Saporiti G, Pini M, Terruzzi E, Arcese W, Marotta G, Carella AM, Nagler A, Russo D, Corradini P, Alessandrino EP, Torelli GF, Scimè R, Mordini N, Oldani E, Marfisi RM, Bacigalupo A, Bosi A.

Lancet Oncol. 2015 Nov;16(15):1525-1536. doi: 10.1016/S1470-2045(15)00200-4. Epub 2015 Sep 28.

46.

Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria.

Kelly RJ, Höchsmann B, Szer J, Kulasekararaj A, de Guibert S, Röth A, Weitz IC, Armstrong E, Risitano AM, Patriquin CJ, Terriou L, Muus P, Hill A, Turner MP, Schrezenmeier H, Peffault de Latour R.

N Engl J Med. 2015 Sep 10;373(11):1032-9. doi: 10.1056/NEJMoa1502950.

47.

Applying complement therapeutics to rare diseases.

Reis ES, Mastellos DC, Yancopoulou D, Risitano AM, Ricklin D, Lambris JD.

Clin Immunol. 2015 Dec;161(2):225-40. doi: 10.1016/j.clim.2015.08.009. Epub 2015 Sep 1. Review.

48.

Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT.

Dufour C, Veys P, Carraro E, Bhatnagar N, Pillon M, Wynn R, Gibson B, Vora AJ, Steward CG, Ewins AM, Hough RE, de la Fuente J, Velangi M, Amrolia PJ, Skinner R, Bacigalupo A, Risitano AM, Socie G, Peffault de Latour R, Passweg J, Rovo A, Tichelli A, Schrezenmeier H, Hochsmann B, Bader P, van Biezen A, Aljurf MD, Kulasekararaj A, Marsh JC, Samarasinghe S.

Br J Haematol. 2015 Nov;171(4):585-94. doi: 10.1111/bjh.13614. Epub 2015 Jul 28.

PMID:
26223288
49.

Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria.

Lin Z, Schmidt CQ, Koutsogiannaki S, Ricci P, Risitano AM, Lambris JD, Ricklin D.

Blood. 2015 Aug 13;126(7):891-4. doi: 10.1182/blood-2015-02-625871. Epub 2015 Jun 16.

50.

Current and future pharmacologic complement inhibitors.

Risitano AM.

Hematol Oncol Clin North Am. 2015 Jun;29(3):561-82. doi: 10.1016/j.hoc.2015.01.009. Epub 2015 Apr 4. Review.

PMID:
26043392

Supplemental Content

Loading ...
Support Center